Cisplatin (cis-diamminedichloroplatinum II) is one of the most potent chemotherapeutic antitumor drugs. Activity has been demonstrated against a variety of neoplasms, particularly for head and neck, testicular, ovarian, bladder and small-cell lung cancers. Cisplatin also has been shown to be effective against virally-induced, chemically-induced and transplantable tumours in animals. High doses of cisplatin produce hepatotoxicity, but the impairment of kidney function by cisplatin is recognized as the main side-effect and the most important dose-limiting factor. The alterations induced by cisplatin in the kidney functions were characterized by signs of injury, such as changes in urine volume, in glutathione status, increase of products of lipid peroxidation, and changes in creatinine clearance.